Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits

Cardiovascular Pathology

Volumn 18, Issue 3, 2009, Pages 140-147

  Jeanpierre, Emmanuelle ^a,b,c,d   Le Tourneau, Thierry ^a,b,c,d   Zawadzki, Christophe ^a,b,c,d   Van Belle, Eric ^a,b,c,d   Mouquet, Frederic ^a,b,c,d   Susen, Sophie ^a,b,c,d   Ezekowitz, Michael D ^e   Staels, Bart ^a,b,f   Jude, Brigitte ^a,b,c,d   Corseaux, Delphine ^a,b,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c Institut Federatif de Recherche 114   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Fibrates; Tissue factor

Indexed keywords

CHOLESTEROL; FENOFIBRATE; FIBRINOGEN; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HISTOLOGY; ILIAC ARTERY; IN VIVO STUDY; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RABBIT; THROMBOGENICITY; THROMBOSIS; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

EID: 65049084170     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2008.03.001     Document Type: Article

References (31)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
2. Ruf W., and Edgington T.S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 8 6 (1994) 385-390
3. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 86 8 (1989) 2839-2843
4. Toschi V., Gallo R., Lettino M., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 3 (1997) 594-599
5. Ardissino D., Merlini P.A., Bauer K.A., et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 98 9 (2001) 2726-2729
6. Marmur J.D., Thiruvikraman S.V., Fyfe B.S., et al. Identification of active tissue factor in human coronary atheroma. Circulation 94 6 (1996) 1226-1232
7. Mackman N. Regulation of the tissue factor gene. FASEB J 9 10 (1995) 883-889
8. Neve B.P., Corseaux D., Chinetti G., et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 2 (2001) 207-212
9. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 19 (1998) 2088-2093
10. Lefebvre P., Chinetti G., Fruchart J.C., and Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116 3 (2006) 571-580
11. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 24 (1999) 3125-3131
12. Jackson S.M., Parhami F., Xi X.-P., et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19 9 (1999) 2094-2104
13. Delerive P., De Bosscher K., Besnard S., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274 45 (1999) 32048-32054
14. Inoue I., Shino K., Noji S., Awata T., and Katayama S. Expression of peroxisome proliferator-activated receptor [alpha] (PPAR[alpha]) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246 2 (1998) 370-374
15. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 6 (1999) 410-418
16. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 10 (2005) 1154-1160
17. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
18. Jeanpierre E., Le Tourneau T., Six I., et al. Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factor. Circulation 108 14 (2003) 1740-1745
19. Kakuta T., Currier J.W., Haudenschild C.C., Ryan T.J., and Faxon D.P. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 89 6 (1994) 2809-2815
20. Le Tourneau T., Van Belle E., Corseaux D., et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. J Am Coll Cardiol 33 3 (1999) 876-882
21. Hennuyer N., Poulain P., Madsen L., et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 99 18 (1999) 2445-2451
22. Duez H., Chao Y.S., Hernandez M., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277 50 (2002) 48051-48057
23. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 22 (2002) 2597-2604
24. Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A., and Allen T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49 4 (2006) 766-774
25. Seki N., Bujo H., Jiang M., et al. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis 178 1 (2005) 1-7
26. Corti R., Osende J., Hutter R., et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 190 1 (2007) 106-113
27. Goetze S., Eilers F., Bungenstock A., et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293 5 (2002) 1431-1437
28. Kockx M., Gervois P.P., Poulain P., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 93 9 (1999) 2991-2998
29. Kon Koh K., Yeal Ahn J., Hwan Han S., et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174 2 (2004) 379-383
30. Zhao S.-p., and Wu J. Fenofibrate reduces tumor necrosis factor-[alpha] serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clinica Chimica Acta 347 1-2 (2004) 145-150
31. Guerre-Millo M., Gervois P., Raspe E., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275 22 (2000) 16638-16642